Investigating Carvedilol’s Repurposing for the Treatment of Non-Small Cell Lung Cancer via Aldehyde Dehydrogenase Activity Modulation in the Presence of β-Adrenergic Agonists

• Published in: Current Issues in Molecular Biology Vol. 45; no. 10; pp. 7996 - 8012
• Main Authors: Ikhmais, Balqis A, Hammad, Alaa M, Abusara, Osama H, Hamadneh, Lama, Abumansour, Hamza, Abdallah, Qasem M, Ibrahim, Ali I. M, Elsalem, Lina, Awad, Mariam, Alshehada, Rahaf
• Format: Journal Article
• Language: English
• Published: MDPI AG 29.09.2023; MDPI
• Subjects: aldehyde dehydrogenase; carvedilol; lung cancer; Lung cancer, Non-small cell; repurposing; Respiratory agents; Sympathomimetic agents; β-agonists; β-blockers; United Kingdom
• ISSN: 1467-3045; 1467-3037; 1467-3045
• DOI: 10.3390/cimb45100505

Repurposing existing drugs appears to be a potential solution for addressing the challenges in the treatment of non-small cell lung cancer (NSCLC). β-adrenoceptor antagonist drugs (β-blockers) have tumor-inhibiting effects, making them promising candidates for potential NSCLC treatment. This study investigates the anticancer potential of a subset of β-blockers in NSCLC cell lines; A549 and H1299. Additionally, it investigates the underlying mechanism behind β-blockers’ anticancer effect by influencing a potential novel target named aldehyde dehydrogenase (ALDH). The MTT assay assessed β-blockers’ cytotoxicity on both cell lines, while Western blot and NADH fluorescence assays evaluated their influence on ALDH protein expression and activity. Carvedilol (CAR) was the most effective blocker in reducing cell survival of A549 and H1299 with IC50 of 18 µM and 13.7 µM, respectively. Significantly, CAR led to a 50% reduction in ALDH expression and 80% decrease in ALDH activity in A549 cells, especially when combined with β-agonists, in comparison to the control. This effect might be attributed to β-agonist blockade or an alternative pathway. This novel finding adds to our understanding of CAR’s multifaceted anticancer properties, implying that combining CAR with β-agonists could be a useful strategy for lung cancer treatment.